دورية أكاديمية
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study.
| العنوان: | Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. |
|---|---|
| المؤلفون: | Roh ME; Institute for Global Health Sciences, Malaria Elimination Initiative, University of California, San Francisco., Zongo I; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Haro A; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Huang L; Department of Clinical Pharmacy, University of California, San Francisco., Somé AF; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Yerbanga RS; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Conrad MD; Department of Medicine, University of California, San Francisco., Wallender E; Department of Clinical Pharmacy, University of California, San Francisco., Legac J; Department of Medicine, University of California, San Francisco., Aweeka F; Department of Clinical Pharmacy, University of California, San Francisco., Ouédraogo JB; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.; Institut des Sciences et Techniques, Bobo-Dioulasso, Burkina Faso., Rosenthal PJ; Department of Medicine, University of California, San Francisco. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2023 Oct 03; Vol. 228 (7), pp. 926-935. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Malaria*/epidemiology , Malaria*/prevention & control , Malaria*/drug therapy , Antimalarials*/therapeutic use , Antimalarials*/pharmacology, Humans ; Child ; Infant ; Child, Preschool ; Burkina Faso/epidemiology ; Case-Control Studies ; Seasons ; Sulfadoxine/therapeutic use ; Amodiaquine/therapeutic use ; Chemoprevention/methods ; Drug Combinations ; Drug Resistance |
| مستخلص: | Background: Despite scale-up of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) in children 3-59 months of age in Burkina Faso, malaria incidence remains high, raising concerns regarding SMC effectiveness and selection of drug resistance. Using a case-control design, we determined associations between SMC drug levels, drug resistance markers, and presentation with malaria. Methods: We enrolled 310 children presenting at health facilities in Bobo-Dioulasso. Cases were SMC-eligible children 6-59 months of age diagnosed with malaria. Two controls were enrolled per case: SMC-eligible children without malaria; and older (5-10 years old), SMC-ineligible children with malaria. We measured SP-AQ drug levels among SMC-eligible children and SP-AQ resistance markers among parasitemic children. Conditional logistic regression was used to compute odds ratios (ORs) comparing drug levels between cases and controls. Results: Compared to SMC-eligible controls, children with malaria were less likely to have any detectable SP or AQ (OR, 0.33 [95% confidence interval, .16-.67]; P = .002) and have lower drug levels (P < .05). Prevalences of mutations mediating high-level SP resistance were rare (0%-1%) and similar between cases and SMC-ineligible controls (P > .05). Conclusions: Incident malaria among SMC-eligible children was likely due to suboptimal levels of SP-AQ, resulting from missed cycles rather than increased antimalarial resistance to SP-AQ. Competing Interests: Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Nat Commun. 2021 Nov 18;12(1):6714. (PMID: 34795281) Acta Paediatr Suppl. 2006 Apr;450:76-85. (PMID: 16817681) Acta Trop. 2016 Dec;164:329-336. (PMID: 27647575) J Infect Dis. 2017 Feb 15;215(4):631-635. (PMID: 28039354) Trends Parasitol. 2013 Oct;29(10):505-15. (PMID: 24028889) Pharmacol Rev. 2005 Mar;57(1):117-45. (PMID: 15734729) Clin Pharmacol Ther. 2020 May;107(5):1179-1188. (PMID: 31652336) Expert Rev Vaccines. 2014 Dec;13(12):1571-91. (PMID: 25348015) Malar J. 2016 Jun 23;15:335. (PMID: 27339129) Epidemiology. 2022 Mar 1;33(2):e7-e8. (PMID: 34799477) Trop Med Infect Dis. 2022 Aug 29;7(9):. (PMID: 36136625) Antimicrob Agents Chemother. 2020 Nov 17;64(12):. (PMID: 33020152) J Antimicrob Chemother. 2015 Sep;70(9):2566-71. (PMID: 26080363) Malar J. 2021 Jun 30;20(1):292. (PMID: 34193148) J Infect Dis. 2008 Jun 1;197(11):1598-604. (PMID: 18471065) Lancet. 2020 Dec 5;396(10265):1829-1840. (PMID: 33278936) PLoS Med. 2020 Aug 21;17(8):e1003214. (PMID: 32822362) Eur J Clin Pharmacol. 2010 Oct;66(10):1025-35. (PMID: 20552179) J Infect Dis. 2018 Aug 14;218(6):946-955. (PMID: 29718283) Clin Pharmacol Ther. 2019 Dec;106(6):1299-1309. (PMID: 31152555) Malar J. 2009 May 04;8:89. (PMID: 19413906) Lancet Infect Dis. 2015 Jun;15(6):692-702. (PMID: 25788162) Nature. 2014 Jan 2;505(7481):50-5. (PMID: 24352242) Sci Rep. 2017 Aug 7;7(1):7389. (PMID: 28785011) PLoS Med. 2021 Sep 8;18(9):e1003727. (PMID: 34495978) Lancet Infect Dis. 2023 Mar;23(3):361-370. (PMID: 36328000) Epidemiology. 2019 Nov;30(6):838-844. (PMID: 31430265) Antimicrob Agents Chemother. 2015;59(6):3018-30. (PMID: 25753626) Antimicrob Agents Chemother. 2018 Apr 26;62(5):. (PMID: 29463542) |
| معلومات مُعتمدة: | R01 AI117001 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: amodiaquine; antimalarial resistance; malaria; seasonal malaria chemoprevention; sulfadoxine-pyrimethamine |
| المشرفين على المادة: | 0 (Antimalarials) 88463U4SM5 (Sulfadoxine) 220236ED28 (Amodiaquine) 0 (Drug Combinations) |
| تواريخ الأحداث: | Date Created: 20230523 Date Completed: 20231005 Latest Revision: 20240524 |
| رمز التحديث: | 20240524 |
| مُعرف محوري في PubMed: | PMC10547452 |
| DOI: | 10.1093/infdis/jiad172 |
| PMID: | 37221018 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiad172 |